Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-05-12FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for XOFIGO (radium-223 dichloride) from Bayer HealthCare Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2015-04-27Clinical Trial Update: Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC
This completed clinical trial reports on the duration of suppression of bone turnover after treatment with zoledronic acid in men with metas…
-
CLINICAL_TRIALS withdrawal · 2015-04-20Clinical Trial Update: AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 2]
A Phase 2 clinical trial evaluating AMG 208 for the tumor microenvironment in metastatic castration-resistant prostate cancer has been withd…
-
CLINICAL_TRIALS trial_result · 2015-04-09Clinical Trial Update: Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 3]
Phase 3 trial results for abiraterone acetate in asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer are post…
-
FDA approval · 2015-03-20FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ZYTIGA (abiraterone acetate) from Janssen Biotech, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-03-05Clinical Trial Update: Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel [Phase 2]
A completed Phase 2 study evaluating ILX651 in patients with castration-resistant prostate cancer who were previously treated with docetaxel…
-
FDA approval · 2015-02-16FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Xofigo (radium-223 dichloride) to expand its approved indication for metastatic castration-resis…
-
CLINICAL_TRIALS trial_result · 2015-02-13Clinical Trial Update: A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC) [Phase 1, Phase 2]
This update reports results from a Phase I/II study of TRC105 in metastatic castration-resistant prostate cancer. The trial has completed an…
-
CLINICAL_TRIALS trial_result · 2015-01-22Clinical Trial Update: Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate [Phase 2]
This Phase 2 trial evaluated a combination of estramustine, docetaxel, and zoledronate in men with hormone-refractory prostate cancer and ha…
-
FDA approval · 2015-01-20FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for ZYTIGA (abiraterone acetate) from Janssen Biotech, Inc., updating the labeling per the suppl…
-
FDA label_change · 2015-01-05FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for JEVTANA (cabazitaxel) filed by Sanofi-Aventis U.S. LLC, resulting in changes to its labeling.
-
CLINICAL_TRIALS trial_result · 2014-11-24Clinical Trial Update: Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel [Phase 2]
A Phase 2 trial evaluating cabazitaxel plus prednisone with octreotide for castration-resistant prostate cancer previously treated with doce…
-
CLINICAL_TRIALS trial_result · 2014-11-17Clinical Trial Update: Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide [Phase 2]
Phase 2 trial assessing the effect of enzalutamide (MDV3100) on androgen signaling and anti-tumor activity in metastatic castration-resistan…
-
CLINICAL_TRIALS trial_result · 2014-11-14Clinical Trial Update: A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC) [Phase 1, Phase 2]
Clinical trial update shows completion of a Phase I/II study of ODX (Osteodex) in metastatic castration-resistant prostate cancer.
-
CLINICAL_TRIALS trial_result · 2014-11-11Clinical Trial Update: A Phase I Study of LFA102 in Japanese Patients [Phase 1]
This update notes that a Phase I trial of LFA102 in Japanese patients has been completed, evaluating castration-resistant prostate cancer an…
-
CLINICAL_TRIALS trial_result · 2014-10-13Clinical Trial Update: Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer [Phase 1, Phase 2]
This clinical trial update reports termination of a Phase 1/2 study of temsirolimus intended to reverse androgen insensitivity in castration…
-
CLINICAL_TRIALS trial_result · 2014-10-03Clinical Trial Update: AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy [Phase 2]
Phase 2 trial evaluating saracatinib (AZD0530) in hormone-resistant/recurrent prostate cancer has completed, with results posted in 2014.
-
CLINICAL_TRIALS research · 2014-09-25Clinical Trial Update: Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC)
The Janssen Research & Development trial to assess treatment patterns in metastatic castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2014-09-08Clinical Trial Update: Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy [Phase 2]
A Phase 2 trial of itraconazole in castration-resistant prostate cancer after chemotherapy was terminated, with results posted in 2014.
-
CLINICAL_TRIALS research · 2014-08-05Clinical Trial Update: Molecular Phenotype Changes and Personalized Treatment for CRPC [NA]
This clinical trial update discusses molecular phenotype changes and personalized treatment strategies for castration-resistant prostate can…
-
CLINICAL_TRIALS withdrawal · 2014-07-23Clinical Trial Update: Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) [Phase 1, Phase 2]
Phase Ib/II trial evaluating orteronel with itraconazole in men with castration-resistant prostate cancer has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2014-07-14Clinical Trial Update: Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Radium-223 dichloride (BAY88-8223) trial in castration-resistant prostate cancer with bone metastases is no longer available.
-
CLINICAL_TRIALS trial_result · 2014-06-23Clinical Trial Update: Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy [Phase 2]
Phase 2 trial evaluating eribulin mesylate in hormone-refractory/metastatic prostate cancer. The study is completed and results were posted …
-
CLINICAL_TRIALS trial_result · 2014-06-19Clinical Trial Update: Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer. [Phase 1]
A completed Phase 1 study of the AKT inhibitor AZD5363 (ipatasertib) in metastatic castration-resistant prostate cancer. The trial evaluated…
-
CLINICAL_TRIALS trial_result · 2014-06-12Clinical Trial Update: A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) [Phase 2]
Phase 2 safety and efficacy study of siltuximab in men with metastatic castration-resistant prostate cancer was terminated; results were pos…